Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 13.9% of the patients who received trastuzumab deruxtecan (grade 1 or 2 in 33 patients and grade 3 in 1) and in 1.3% ...

Trastuzumab deruxtecan (DS-8201) ... (21% and 11%). A total of 12 patients had trastuzumab deruxtecan–related interstitial lung disease or pneumonitis ...

Trastuzumab deruxtecan reduced risk for disease progression or death compared with trastuzumab emtansine among patients with HER2-positive metastatic breast cancer previously treated with ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) ... Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU.

High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demons ...